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Epidemiology
About 30,000 Americans develop pancreatic cancer each year
and 30,000 die from it. A large number of case-control and
cohort studies have shown that there is a clustering of pancre-
atic cancer in some families and that this clustering occurs more
frequently than one would expect by chance (Ghadirian et al.,
2002; Tersmette et al., 2001; Coughlin et al., 2000). For exam-
ple, Tersmette et al. followed over 340 kindreds enrolled in the
National Familial Pancreas Tumor Registry (NFPTR) and found
an 18-fold increased risk of pancreatic cancer in the kindreds in
which at least a pair of first-degree relatives had been diag-
nosed with pancreatic cancer at the time the kindred enrolled in
the NFPTR. More recently, segregation analyses have suggest-
ed that this clustering of pancreatic cancer has a genetic basis.
In a complex segregation analysis on 287 families ascertained
through an index case diagnosed with pancreatic cancer at the
Johns Hopkins Medical Institutions between January 1, 1994,
and December 31, 1999, nongenetic transmission models (p <
0.0001) were rejected and the most parsimonious models
included autosomal dominant inheritance of a rare allele.
Approximately 0.5% of the population is estimated to carry this
allele. Five genetic syndromes associated with an increased
risk of pancreatic cancer have already been identified. These
five syndromes are listed in Table 1 and include (1) BRCA2; (2)
familial atypical multiple mole melanoma (p16/CDKN2A) (Lynch
et al., 2002); (3) Peutz-Jeghers Syndrome, which is character-
ized by melanocytic macules on the lips and bucal mucosa and
numerous hamartomatous polyps of the gastrointestinal tract
(Giardiello et al., 2000); (4) hereditary nonpolyposis colorectal
syndrome (HNPCC) (Wilentz et al., 2000); and (5) familial pan-
creatitis (Lowenfels et al., 1997). These five syndromes only
account for ?20% of the families in which there is an aggrega-
tion of pancreatic cancer. The hunt for the gene or genes
responsible for the aggregation of pancreatic cancer in the
majority of the families is one of the most exciting areas of pan-
creatic cancer research at the present time.
Disease mechanism and variant tumors
The pancreas is an extremely common site for the development
of early neoplasms—noninvasive clonal epithelial expansions
termed pancreatic intraepithelial neoplasia (PanIN) are
extremely common in elderly persons (Hruban et al., 2000). In a
minority of persons, these clones of cells serially acquire genet-
ic changes that can lead to an invasive adenocarcinoma (Table
2). The epithelial cells in the advanced stage of this process are
very aggressive, seemingly having an innate capability for
metastasis that is exhibited rather soon after they invade
beyond the duct structure into surrounding tissue. This invasion
is nearly always accompanied by an exuberant nonneoplastic
stromal response termed “desmoplasia” that generally accounts
for the majority of the tumor volume (Wilentz, et al., 2000). In
most cases, the cancer is a conventional ductal adenocarcino-
ma that arises from a high-grade PanIN lesion. There are also
variants. The intraductal papillary mucinous neoplasm (IPMN)
arises in the large pancreatic ducts and produces copious
amounts of extracellular mucin. Medullary carcinomas have a
distinct undifferentiated histologic appearance. Tumors with
endocrine differentiation are usually treated as an entirely sepa-
rate category of disease.
Key genes and pathways involved in the pathogenesis of
pancreatic cancer
The conventional infiltrating ductal adenocarcinomas have all
the accoutrements of widespread chromosomal instability
(CIN), including a high rate of translocations and deletions
(Hilgers and Kern, 1999). Nearly all have a mutation in the
KRAS2 (K-ras) G protein involved in the transmission of growth
factor signals and inactivation of the CDKN2A (p16) cyclin-
dependent kinase inhibitor. Most also harbor mutations of the
TP53 (p53) gene and in MADH4, the common Smad protein
involved in transduction of TGFβ and activin signals. Additional
recurrent patterns of gene mutation are seen at lower frequen-
cies (Table 2). BRCA2 mutations are usually inherited, rather
than acquired (Goggins et al., 1996), while CDKN2A and LKB1
mutations can be germline or, much more often, acquired.
Medullary cancers differ from the above pattern, often having a
wild-type KRAS2 gene and often with evidence of DNA mis-
match-repair defects (Goggins et al., 1998; Yamamoto et al.,
2001). The latter are due to mutation or methylation of DNA
repair genes MSH2 or MLH1, defects that can be inherited as a
cause of genetic cancer susceptibility. These tumors lack the
deletions that would be evidence of chromosomal instability,
Table 1. Genetic disorders and germline genetic alterations associated
with familial pancreatic cancer
Increased risk
Disorder Gene location of pancreas cancer
Hereditary pancreatitis PRSS1 (7q35) 50×
Hereditary nonpolyposis MSH2, MLH1 ?
colorectal cancer lynch
variant II
Hereditary breast and BRCA2 (13q12-q13) 3.520×
ovarian cancer
Familial atypical multiple p16 (9p21) 1220×
mole melanoma 
syndrome (FAMMM)
Peutz-Jeghers syndrome STK11/LKB1 (19p13) 130×
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although they commonly have mutations of genes that contain
simple nucleotide repeats, such as in the TGFBR1 and BAX
genes.
Techniques are now available to comprehensively profile
the gene expression patterns of pancreatic cancer. The use of
serial analysis of gene expression (SAGE) and gene microarray
technologies have identified a number of genes overexpressed
by pancreatic cancers. For example, mesothelin is highly
expressed in nearly all, and prostate stem cell antigen in most,
ductal adenocarcinomas of the pancreas (Figure 1; Argani et
al., 2001a, 2001b). Both are cell surface proteins that can also
be secreted. These and other proteins secreted by the tumor,
such as connective tissue growth factor, suggest a communica-
tion between the neoplastic epithelial cells and nonneoplastic
stromal cells, perhaps accounting for the distinctive desmoplas-
tic reaction present in conventional ductal pancreatic cancers
(Iacobuzio-Donahue et al., 2002; Goggins et al., 2000).
Screening and diagnosis
Abdominal examination and standard radiologic imaging tests
such as transabdominal ultrasonography, magnetic resonance
imaging (MRI), and conventional spiral CT scan are not suffi-
ciently sensitive for small early cancers, even in symptomatic
patients (AGA, 1999). Therefore, routine pancreatic cancer
screening is not recommended in asymptomatic persons (AGA,
1999). However, subgroups at increased risk (individuals with
inherited genetic syndromes and those from familial pancreatic
cancer kindreds) might benefit from screening.The most optimal
method for screening is unknown and is currently under evalua-
tion. Endoscopic ultrasonography (EUS) has been suggested as
one radiologic imaging modality that may potentially detect pan-
creatic neoplasia. EUS is high-frequency, real-time ultrasonogra-
phy combined with endoscopy. It is currently one of the best
imaging modalities for the pancreas. It is associated with a very
low risk of adverse effects (0%–0.5%) and very high sensitivity
for detection of early pancreatic cancer (Grimm et al., 1990;
Nakaizumi et al., 1995). Brentnall and colleagues first reported
the use of EUS for screening relatives from familial pancreatic
cancer kindreds.They found that EUS had a high positive predic-
tive value for dysplasia in high-risk persons (Brentnall et al.,
1999). Seven patients who had both EUS and endoscopic retro-
grade cholangiopancreography (ERCP) abnormalities un-
derwent total pancreatectomy, and widespread epithelial ductal
dysplasia (low-grade to high-grade) involving the small- and
medium-sized ducts were found in all. The authors of this study
recommend EUS as the preferred screening test because of the
risk for pancreatitis associated with ERCP.
Prospective studies are currently underway to evaluate the
feasibility and diagnostic yield of EUS- and spiral CT-based
screening of high-risk individuals coupled with collection and
banking of various tissue specimens for future molecular mark-
er analyses. At Johns Hopkins, a screening and early detection
program for high-risk individuals from kindreds with familial pan-
creatic cancer (National Familial Pancreas Tumor Registry) and
patients with Peutz-Jeghers syndrome (Hereditary Colorectal
Cancer Registry) is ongoing (Canto et al., 2002). EUS is per-
formed and if EUS is abnormal, EUS-guided fine-needle aspira-
tion (FNA), ERCP, and dual-phase, thin-section spiral CT are
performed. Patients with a mass are referred for surgery, while
those with other abnormalities undergo repeat EUS/FNA within
3–6 months. Thirty-seven patients with no symptoms referable
to the pancreas or suggestive of cancer have been screened.
Six pancreatic masses have been found by EUS (4/6 also
detected by CT scan)—1 adenocarcinoma, 1 benign intraductal
papillary mucinous tumor, and 4 nonneoplastic lesions.The one
patient from a family with six pancreatic cancers who was diag-
nosed by EUS with pancreatic cancer was resected and is still
alive and disease-free 3 years from diagnosis. The diagnostic
yield of screening for a pancreatic neoplasm was 2/37 = 5.4%.
Current therapeutic strategies
Pancreaticoduodenectomy provides the only chance for cure.
Table 2. Molecular alterations in pancreatic ductal neoplasia
Gene (chromosome) Alterationa Frequency in cancersb Appearance in preinvasive lesionsc
CDKN2A (9p) Mutation, silencing 95% Middle
KRAS2 (12p) Activating mutation 95% Early
TP53 (17p) Mutation 50%75% Late
MADH4 (18q) Mutation 55% Late
EP300 (22q) Mutation 25%
AKT2 (19q) Amplification 15%
MYB (6q) Amplification 10%
BRCA2 (13q) Mutation 7% Late
LKB1/STK11 (19p) Mutation 5%
MKK4 (17p) Mutation 4%
RB1 (13q) Mutation rare
TGFBR1 (9q) Mutation, underexpression 2%
TGFBR2 (3p) Mutation, underexpression 4%7%
ACVR1B (12q) Mutation 2%
BAX (19q) Mutation 6%
MSH2 or MLH1 Mutation, silencing 3%15%
Mesothelin Overexpression 95% Rare
PSCA Overexpression 75% Early
Her2/neu Overexpression Middle
aMutation refers to homozygous inactivating intragenic mutations and homozygous deletions, the exceptions being KRAS2, which has mutations of
codons 12, 13, and 61 that activate its signaling function, and the amplified genes. Silencing refers to a total loss of gene expression in the absence of
genetic mutation, usually associated with methylation of the gene promoter. Mutations that do not occur at a frequency higher than explicable by
chance, and some unconfirmed gene mutations, are omitted.
bMost TGFBR2 and all Bax mutations reported represent microsatellite mutations in tumors having MSH2 or MLH1 alterations. Underexpression of TGFβ recep-
tors is widespread; the mutational frequency alone is given here.
cIn the case of BRCA2, the first mutation is germline, while the loss of the wild-type allele appears to be a late event in tumorigenesis.
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However, few options exist for the 80% of patients with locally
advanced or metastatic disease at diagnosis. Prolonged sur-
vival has been observed in a small subset of pancreatic cancer
patients treated with Gemcitabine either alone or in combination
with other chemotherapeutic agents such as Cisplatin and
Paclitaxel (Rosenberg, 2000, Laheru et al., 2001).
Experimental therapeutic approaches
Molecular technology advances have ushered in a new age of
targeted novel approaches that should translate rapidly into
new therapeutic options for patients with pancreatic cancer.
Some of these new approaches aim to specifically inhibit tumor
growth and metastases by targeting specific components of the
tumor’s microenvironment and selected signal transduction
pathways. Other approaches aim to augment antitumor immuni-
ty to specific antigenic targets.
Targets in the tumor microenvironment
Evidence suggests that matrix metalloproteinases (MMP)
facilitate early pancreatic tumor invasion and metastasis.
Several MMPs have been shown to be overexpressed by neo-
plastic pancreatic epithelium and the desmoplastic stromal
cells. A small molecule inhibitor of MMP, Marimastat, is cur-
rently undergoing phase II testing in inoperable pancreatic
cancer patients (Rosenberg, 2000). Angiogenesis is also criti-
cal for the growth of primary tumors and is essential to the
metastatic process. Several pancreatic cancer-associated
genes have been linked to angiogenesis. DPC4 upregulates
vascular endothelial growth factor expression, and mutated K-
ras expression is associated with increased microvessel den-
sity (Schwarte-Waldhoff et al., 2000). These angiogenesis
pathways provide new targets for therapeutic intervention that
are currently being explored. One major challenge will be to
identify targets that are specifically altered relative to the nor-
mal counterpart so as to avoid significant treatment-related
toxicities.
Signal transduction inhibition
The K-ras oncogene product and its signaling pathway has
been a major focus of pancreatic research. Some ras proteins
require a posttranslational 15-carbon farnesyl group addition
to bind to the cell membrane for signal-
ing to occur. Inhibitors designed to block
the addition of the farnesyl group have
been demonstrated to inhibit pancreatic
cancer growth in preclinical in vitro and
in vivo models. However, early clinical
trials have not demonstrated significant
activity against pancreatic cancers (Hao
and Rowinsky, 2002). Interestingly,
other signaling molecules rather than
mutated KRAS2 may turn out to be 
the target of the farnesyltransferase
inhibitors, since these inhibitors appear
to have activity in nonmutated ras-
expressing tumors. The identification of
additional signaling pathways specifi-
cally upregulated in pancreatic cancers
should be forthcoming from the gene discovery studies
described earlier.
Immunotherapy
Immunotherapy represents a noncrossresistant mechanism of
antitumor activity that can be integrated with surgery, radiation
therapy, and chemotherapy. A number of preclinical studies
have been published demonstrating synergistic activity
between immune-based therapy and other cancer treatment
modalities (Emens et al., 2001). Antibody-based therapy has
been studied against a few pancreatic cancer antigens and has
demonstrated some activity (Laheru et al., 2001). Active immu-
nization with whole tumor cells that have been genetically mod-
ified to express cytokines or other costimulatory molecules are
an attractive approach that has demonstrated significant poten-
cy in animal models. Recently, an allogeneic granulocyte-
macrophage colony-stimulating factor-secreting tumor vaccine
was tested in 14 stage 2 or 3 patients who underwent a Whipple
procedure. The vaccine was demonstrated to be safe and to
induce tumor-specific immunity in 3 of 8 patients receiving 108
and 5 × 108 vaccine cells (Jaffee et al., 2001). Immunization with
heat shock proteins (HSP) isolated from pancreatic tumor cells
is another important approach that is undergoing clinical testing
(Laheru et al., 2001). Vaccine and antibody approaches target-
ing pancreatic cancer-associated tumor antigens (CEA, 
MUC-1, and mutated KRAS) have also undergone clinical test-
ing. Although toxicities were minimal, these approaches so far
have failed to generate clinical responses (Laheru et al., 2001).
Future challenges
Cancer research focused on deciphering the human genome
sequence is dissecting the pathobiology of pancreatic cancer
and is leading to new targets for diagnosis, prevention, and ther-
apy. This new era raises new challenges for translating these
new discoveries. New animal models are required for under-
standing the biologic significance of identified genetic path-
ways, for rapidly evaluating potential new therapies, and for
revealing potential synergistic interactions among interventions
that target multiple biologic pathways. In addition, innovative
clinical trial designs are required that incorporate new end-
Figure 1. Immunohistochemistry staining of a
pancreatic cancer for PSCA expression
Normal glands are shown in the center of the
photo (unlabeled areas), and invasive cancer is
on the sides (labeled areas).
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points for evaluating these new therapeutic interventions that
are cancer specific. To this end, noninvasive methods for repeti-
tive sampling of tissues from treated patients and for imaging
biologic responses are also essential.
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